The Evolving Role of CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

Bijal Shah, MD, MS, and Jae Park, MD, discuss other key data in acute lymphoblastic leukemia from EHA 2025.

Bijal Shah, MD, MS, and Jae Park, MD, discuss quality-of-life data for obe-cel in acute lymphoblastic leukemia.